Bleeding in Laparoscopic Liver Surgery (MODELS)
Neuromuscular Blockade, Intraoperative Bleeding, Hepatic Cancer

About this trial
This is an interventional treatment trial for Neuromuscular Blockade focused on measuring liver surgery, bleeding, neuromuscular blockade, rocuronium, airway pressure
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing laparoscopic liver resection
- Patients ≥ 18 years old
- Patients willing to participate to the study and able to validly sign informed consent.
Exclusion Criteria:
- Patients presenting a pre-operative platelet count < 50 x 109/L and/or patients with active pre-operative bleeding
- Patients with planned requirement of continuous neuromuscular blockade monitoring (upon clinical judgement)
- Known hypersensitivity / previous allergic reactions to study medications
- Planned total intra-venous anesthesia technique
- Pregnant or breastfeeding patients.
Sites / Locations
- Ospedale San RaffaeleRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Deep neuromuscular blockade
Moderate neuromuscular blockade
During surgery, deep neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring, aiming for a Post-Tetanic Count (PTC) = 0 or PTC = 1 and Train of Four Count (TOFC) = 0. TOF and PTC measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored PTC is > 1. Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided.
During surgery, a moderate neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring. TOF and Post-Tetanic Count (PTC) measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored TOF count is ≥ 1 and/or PTC > 5. Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided.